Sanofi CEO Garijo Takes Helm Amid Immunology Results
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Garijo assumes the Sanofi CEO role this month, inheriting a pipeline heavily weighted toward immunology.
- Sanofi's recent immunology push has produced lackluster trial outcomes, prompting analysts to anticipate a strategic rebalance.
- STAT+ highlights broader biotech trends, noting a gene‑therapy for deafness entering real‑world use and ultra‑cheap telehealth raising care‑quality concerns.
Why it matters: Not enough in the article to say why this matters.
